Autres langues FUSN PHAR

Actions

FUSN

CA36118A1003

Temps réel estimé Cboe BZX Autres places de cotation 20:45:55 21/05/2024			Varia. 5j.	Varia. 1 janv.
21,5 ^USD	-0,14 %		+0,44 %	+123,99 %

09/05	Fusion Pharmaceuticals Inc. Fusion Pharmaceuticals Inc. annonce que le premier patient a été traité dans le cadre de la phase 2 de l'essai AlphaBreak évaluant le FPI-2265 dans le cancer de la prostate métastatique résistant à la castration.	CI
07/05	Fusion Pharmaceuticals Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	09/05
Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	09/05
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN	09/05
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
Fusion Pharmaceuticals Reports First Quarter 2024 Financial Results and Announces Clinical Program Updates	07/05
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	25/04
Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order	25/04
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	09/04
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024	09/04
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN	27/03
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca	20/03
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	20/03
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	20/03
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates	20/03
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN	20/03
Sector Update: Health Care Stocks Rise Late Afternoon	19/03
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	19/03
Sector Update: Health Care	19/03
Top Midday Gainers	19/03
Top Stories at Midday: February US Housing Starts Rise; AstraZeneca to Acquire Fusion Pharmaceuticals; IFF to Sell Pharma Solutions Unit; Unilever to Spin Off Ice Cream Unit; MicroStrategy Completes Notes Offering; Super Micro Computer Files Shelf; Nvidia Unveils Latest GPU	19/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues FUSN PHAR

Actions

FUSN

CA36118A1003

Autres langues

Filtres